Digital therapeutics firm Click Therapeutics will acquire the assets of Better Therapeutics, including a mobile app for Type 2 diabetes patients called AspyreRx, following approval by the FDA. The acquisition comes after Better announced the layoff of all its employees due to lack of capital reserves. Click aims to develop a digital therapeutic for obesity using the acquired assets in combination with metabolic disorder medications.
‘Amber alert’ as NHS in Plymouth makes urgent plea for people with certain blood type
The NHS has issued an urgent call for O type blood donors, following increased demand after the recent cyber attack. The attack led to reduced
